mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease

Contributed by: PR Newswire

Tags

mAbxience-Biosidus

More Like This

PR Newswire associated0

Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta

PR Newswire associated0

mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

PR Newswire associated0

Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion

PR Newswire associated0

mAbxience Announces European Commission Approval of Denosumab Biosimilars

PR Newswire associated0

mAbxience Appoints Jurgen Van Broeck as New CEO

PR Newswire associated0

Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets

mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

PR Newswire associated0

mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development